plates (Merck, . Visualization was done using UV light and by spraying with 1% ferric (III) chloride in ethanol, 5% potassium permanganate in water, and anisaldehyde in ethanol and sulfuric acid. Melting points were determined on an MQAPF-301 Digital (MicroQuímica) apparatus and are uncorrected. Purities of final compounds were established by analytical HPLC, which was carried out on a Waters Alliance 2695 (Waters) chromatography system with a PDA 995 detector, a reverse-phase Symmetry C-18 (4.6 x 100 mm, 3.5 m column), and mobile phases of H 2 O with TFA (0.045%), and MeCN with TFA (0.036%), at a flow rate of mL min -1 . All synthetic compounds were of ≥ 95% purity as determined by the method described above (linear gradient 0-100% MeCN over 8 min at 315 nm). HPLC-MS analyses were performed with a Waters 2998 Photodiode Array Detector, a Waters 2695
Separations Module, and a Waters Micromass ZQ ESCi Multimode ionization enabled.
Fluorescence was measured using a Bio-Tek FL600 fluorescence plate reader (Bio-Tek Instruments). POP (EC 3.4.21.26 ) was obtained by expression in E.coli and affinity purification using a His tail fusion following a procedure described in the literature. Porcine DPP IV (EC 3.4.14.5) was purchased from Sigma-Aldrich. Verbascoside (purity 90%) was obtained by isolation from Buddleja brasiliensis Jacq. Ex Spreng [10] . ZGP-AMC (N-benzyloxycarbonyl-Gly-Pro-methylcoumarinyl-7-amide) and GP-AMC (H-Gly-Pro-methylcoumarinyl-7-amide)
were from Bachem, Z-prolyl-prolinal (purity 97.0%) and isoleucine thiazolide (P32/98; purity ≥ 98.0%) were purchased from Enzo Life Sciences.
General synthesis of the derivatives 2-4, 7-8, 10, and 14-15
Chlorogenic acid 1 was esterified using methanol and Amberlite IR120 H resin to obtain 2 as a white solid in 97% yield [16] . Esterification of the corresponding caffeic acid 6, cinnamic acid 12, and p-methoxycinnamic acid 13 were conveniently carried out using the Fischer method, resulting in the derivatives 8, 14, and 15, respectively, in satisfactory yields (60-90%).
Acetylation reactions of 1 and 6 were performed following the method described by Sefkow
[17] and Kim [18] , obtaining derivatives 3 and 10 in 85 and 74% yield, respectively. Compound 4, the 1,7-monoketal of chlorogenic acid, was obtained in 40% yield by the reaction of 1 with acetone followed by selective hydrolysis of 3,4-ketal following the method described by ChaoMei Ma et al. [19] . 3,4-Dimethylcaffeic acid 7 was prepared with Me 2 SO 4 in NaOH as described by Li and Xu [20] . All crude derivatives were purified by crystallization or column chromatography over silica gel. The structural characterization of these compounds was performed using spectrometric and spectroscopic data (MS, optical rotation, 1 H NMR and 13 C NMR) and compared directly with data found in the literature [17] [18] [19] [20] [21] [22] .
In vitro measurement of enzyme inhibition

POP activity assay
POP activity was determined following the method described by Toide et al. [7] . The reactions were performed in 96-well microplates, thereby allowing the simultaneous monitoring of multiple reactions. For each reaction, the activity buffer (131 L, 100 mM of Na/K phosphate buffer, pH 8.0) was preincubated for 15 min at 37 C with POP (7 nM) and with the corresponding inhibitor solution (3 L). Stock solutions of inhibitors were prepared in DMSO (100 mM), and dilutions were prepared from this stock solution with the activity buffer. After preincubation, ZGP-AMC (10 L, 3 mM in 40% of 1,4-dioxane) was added and the reaction was incubated for 1 h at 37C. The formation of AMC was measured fluorimetrically. Positive and negative controls containing 3 L of the sample in DMSO, 10 L of ZGP-AMC solution,
and 131 L of the activity buffer, with and without 7 nM of POP solution, respectively, were performed. The excitation and emission wavelengths were 360/40 and 485/20 nm, respectively.
The IC 50 value was defined as the concentration of fraction required to inhibit 50% of POP activity. Data were analyzed using GraphPad Prism 6 software. The assay was performed in triplicate and with a blank for each sample without enzyme. Verbascoside and Z-prolyl-prolinal were evaluated as a positive control in the same experimental conditions, and the percentage of inhibition was calculated by comparing the absorbance of the sample to the blank.
DPP IV activity assay
DPP IV activity was determined following the method described by Checler et al. [31] . The reactions were performed in a 96-well microplate. For each well, the reaction mixture contained activity buffer (131 L, 100 mM Na/K phosphate buffer, pH 8.0), 0.7 nM DPP IV, and 3 L of the corresponding solution (in DMSO). After preincubation (15 min at 37 °C), GP-AMC (10 L, 3 mM in 40% 1,4-dioxane) was added, and the reaction was incubated for 1 h at 37 ºC. The formation of AMC was measured fluorimetrically. Positive and negative controls containing 3
L of the sample in DMSO, 10 L of GP-AMC solution, and 131 L of the activity buffer, with and without 0.7 nM of DPP IV solution, respectively, were performed. The excitation and emission wavelengths were 360/40 and 485/20 nm, respectively. The IC 50 value was defined as the concentration of compound required to inhibit 50% of DPP IV activity. Data were analyzed using GraphPad Prism 6 software. Isoleucine thiazolide was used as a positive control. The assay was performed in triplicate and with a blank for each sample without enzyme, and the percentage of inhibition was calculated by comparing the absorbance of the sample to the blank.
Fig. 1S:
13 C NMR spectrum of (E)-methyl 1-(3-(3-(3,4-dihydroxyphenyl)acryloyloxy)-1,4,5-trihydroxycyclohexanecarbonyl)pyrrolidine-2-carboxylate (5) in CD 3 OD.
Fig. 2S:
1 H NMR spectrum of (E)-methyl 1-(3-(3,4-dihydroxyphenyl)acryloyl) pyrrolidine-2-carboxylate (9) in DMSO.
Fig. 3S:
13 C NMR spectrum of ((E)-methyl 1-(3-(3,4-dihydroxyphenyl)acryloyl) pyrrolidine-2-carboxylate (9) in DMSO. .
Fig. 4S:
1 H NMR spectrum of (E)-4-(3-(2-(methoxycarbonyl)pyrrolidin-1-yl)-3-oxoprop-1-enyl)-1,2-phenylene-diacetate (11) in CDCl 3 .
Fig. 5S:
13 C NMR spectrum of (E)-4-(3-(2-(methoxycarbonyl)pyrrolidin-1-yl)-3-oxoprop-1-enyl)-1,2-phenylene-diacetate (11) 
Fig. 8S:
1 H NMR spectrum of (E)-methyl 1-(3-(4-methoxyphenyl)acryloyl)pyrrolidine-2-carboxylate (17) in CDCl 3 .
Fig. 9S:
13 C NMR spectrum of (E)-methyl 1-(3-(4-methoxyphenyl)acryloyl)pyrrolidine-2-carboxylate (17) in CDCl 3 .
Fig. 10S:
1 H NMR spectrum of 1-cinnamoylpyrrolidine-2-carboxylic acid (18) in CD 3 OD.
Fig. 11S:
13 C NMR spectrum of 1-cinnamoylpyrrolidine-2-carboxylic acid (18) in CD 3 OD.
Fig. 1S2:
1 H NMR spectrum of (E)-1-(3-(4-methoxyphenyl)acryloyl)pyrrolidine-2-carboxylic acid (19) in CD 3 OD.
Fig. 13S:
13 C NMR spectrum of (E)-1-(3-(4-methoxyphenyl)acryloyl)pyrrolidine-2-carboxylic acid (19) in CD 3 OD.
